![Seth Ettenberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Seth Ettenberg
Director Ejecutivo en BlueRock Therapeutics Canada ULC .
Perfil
Seth Ettenberg is the President & Chief Executive Officer at BlueRock Therapeutics Canada ULC and the President, Chief Executive Officer & Director at BlueRock Therapeutics LP.
He previously served as the Chief Scientific Officer at Cogent Biosciences, Inc. Dr. Ettenberg holds a doctorate degree from the Uniformed Services University of the Health Sciences.
Cargos activos de Seth Ettenberg
Empresas | Cargo | Inicio |
---|---|---|
BlueRock Therapeutics Canada ULC
![]() BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Director Ejecutivo | 01/08/2021 |
BlueRock Therapeutics LP
![]() BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company is based in Cambridge, MA. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. BlueRock Therapeutics' lead clinical program, Bemdaneprocel (BRT-DA01), is in phase I clinical trials for Parkinson's disease. BlueRock Therapeutics was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG. Seth Ettenberg has been the CEO of the company since 2020. | Director Ejecutivo | 01/08/2021 |
Antiguos cargos conocidos de Seth Ettenberg.
Empresas | Cargo | Fin |
---|---|---|
COGENT BIOSCIENCES, INC. | Director Técnico/Científico/I+D | 02/03/2020 |
Formación de Seth Ettenberg.
Uniformed Services University of the Health Sciences | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
COGENT BIOSCIENCES, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
BlueRock Therapeutics Canada ULC
![]() BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Health Technology |
BlueRock Therapeutics LP
![]() BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company is based in Cambridge, MA. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. BlueRock Therapeutics' lead clinical program, Bemdaneprocel (BRT-DA01), is in phase I clinical trials for Parkinson's disease. BlueRock Therapeutics was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG. Seth Ettenberg has been the CEO of the company since 2020. | Commercial Services |
- Bolsa de valores
- Insiders
- Seth Ettenberg